Mitogen-Activated Protein Kinase Signaling is Activated in Prostate Tumors but not Mediated by B-RAF Mutations

European Urology

Volumn 50, Issue 5, 2006, Pages 1102-1110

  Burger, Maximilian ^a   Denzinger, Stefan ^a   Hammerschmied, Christine ^a   Tannapfel, Andrea ^b   Maderstorfer, Armin ^a   Wieland, Wolf Ferdinand ^a   Hartmann, Arndt ^a   Stoehr, Robert ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

B RAF; MAPK signaling; Microsatellite instability; Prostate cancer

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GLEASON SCORE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

AGED; ALLELES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENZYME ACTIVATION; EXONS; FEMALE; GENOME, HUMAN; GLUTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; VALINE;

EID: 33749253906     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.11.031     Document Type: Article

References (48)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Aus G., Abbou C.C., Bolla M., Heidenreich A., Schmid H.P., van Poppel H., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
3. Shibatta A., and Whittmore A.S. Genetic predisposition to prostate cancer: possible explanation for ethnic differences. Prostate 32 (1997) 65-72
4. Steinberg G.D., Carter B.S., Beaty T.H., Childs B., and Walsh P.C. Family history and the risk for prostate cancer. Prostate 17 (1990) 337-347
5. Eble J.N., and Epstein J.I. Stage A carcinoma of the prostate. In: Bostwick D.G., and Roth L.M. (Eds). Pathology of the Prostate, Seminal Vesicles and Male Urethra (1990), Churchill Livingstone, New York 61-82
6. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogramm for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
7. Bostwick D.G., Grignon D.J., Hammon M.E., Amin M.B., Cohen M., Crawford D., et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus statement. Arch Pathol Lab Med 124 (1999) 995-1000
8. Chong H., Vikis H.G., and Guan K.L. Mechanisms of regulating the Raf kinase family. Cell Signal 15 (2003) 463-469
9. Yang S.H., Sharrocks A.D., and Whitmarsh A.J. Transcriptional regulation by the MAP kinase signalling cascades. Gene 320 (2003) 3-21
10. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-50
11. Chong H., Jeeyong L., and Guan K.L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20 (2001) 3716-3727
12. Dibb N.J., Dilworth S.M., and Mol C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature 4 (2004) 718-727
13. Boettner B., and van Aelst L. The RASputin effect. Genes Dev 15 (2002) 2033-2038
14. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
15. Kimura E.T., Nikiforov Y.A., Zhu Z., Knauf J.A., Nikiforov Y.A., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathway in papillay thyroid carcinoma. Cancer Res 63 (2003) 1454-1457
16. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., and Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62 (2002) 7001-7003
17. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002) 6997-7000
18. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62 (2002) 6451-6455
19. Stoehr R., Brinkmann A., Filbeck T., Gamper C., Wild P., Blaszyk H., et al. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Oncol Rep 11 (2004) 137-141
20. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., et al. High frequency of BRAF mutations in nevi. Nat Genet 33 (2003) 595-602
21. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
22. Domingo E., Niessen R.C., Oliveira C., Alhopuro P., Moutinho C., Espin E., et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005 Mar 21)
23. Maroni P.D., Koul S., Meacham R.B., and Koul H.K. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Commun Signaling 2 (2004) 5
24. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59 (1999) 279-284
25. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8 (2002) 1168-1171
26. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., et al. BRAF mutation in papillary thyroid carcinoma. JNCI 95 (2003) 625-627
27. Stoehr R., Knuechel R., Boecker J., Blaszyk H., Schmitt R., Filbeck T., et al. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab Invest 82 (2002) 1553-1561
28. Epstein J.I., Algaba F., Allsbrook W.C., Bastacky S., et al. Tumors of the prostate. In: Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. (Eds). World Health Organization, Classification of Tumors. Pathology and Genetic. Tumors of the urinary system and male genital organs (2004), IARC Press, Lyon 159-216
29. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumors (1997), Wiley-Liss, New York, Weinheim
30. Stoehr R., Zietz S., Burger M., Filbeck T., Denzinger S., Obermann E.C., et al. Deletions of chromosomes 9 and 8p in histologically normal urothelium in patients with bladder cancer. Eur Urol 47 (2005) 58-63
31. Hartmann A., Stoehr R., Wild P.J., and Knuechel R. Microdissection for detecting genetic alterations in early and advanced human urinary bladder cancer. Methods Mol Biol 293 (2005) 79-92
32. Stoehr R., Krieg R.C., Knuechel R., Hofstaedter F., Pilarsky C., Zaak D., et al. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol 20 (2002) 905-911
33. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
34. Dietmaier W., Wallinger S., Bocker T., Kullmann F., Fishel R., and Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 57 (1997) 4749-4756
35. Schlegel J., Bocker T., Zirngibl H., Hofstaedter F., and Ruschoff J. Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch 426 (1995) 223-237
36. INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 52 (2003) 706-712
37. Bubendorf L., Nocito A., Moch H., and Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195 (2005) 72-79
38. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
39. Church D.R., Lee E., Thompson T.A., Basu H.S., Ripple M.O., Ariazi E.A., et al. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 63 (2005) 155-168
40. Price T.R., delle Rocca G., Guo C., Ballo M.S., Schwinn D.A., and Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162 (1999) 1537-1542
41. Ghosh P.M., Malik S.N., Bedolla R.G., Wang Y., Mikhailova M., Prihoda T.J., et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12 (2005) 119-134
42. Papatsoris A.G., and Papavassiliou A.G. Molecular palpation of BPH: a tale of MAPK signalling?. TREND Mol Med 7 (2001) 288-292
43. Ayala G., Thompson T., Yang G., Frolov A., Li R., Scardino P., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10 (2004) 6407-6410
44. Weber M.J., and Gioeli D. Ras signalling in prostate cancer progression. J Cell Biochem 91 (2004) 13-25
45. Ahman A.K., Jonsson B.A., Damber J.E., Bergh A., and Grönberg H. Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int 87 (2001) 334-338
46. Rebbeck T.R. Genetics, disparities and prostate cancer. LDI issue Brief 10 (2005) 1-4
47. Sacco E., Prayer-Galetti T., Pinto F., Ciaccia M., Fracalanza S., Betto G., and Pagano F. Familial and hereditary prostate cancer by definition in an Italian surgical series: clinical features and outcome. Eur Urol 47 (2005) 761-768
48. Scott R.J., McPhillips M., Meldrum C.J., Fitzgerald P.E., Adams K., Spigelman A.D., et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 68 (2001) 118-127